@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RAiajNiRuWoUJQ5syzRVZA7flSXq7zYpnhCRbOi5gBmbY> .
@prefix sub: <http://purl.org/np/RAiajNiRuWoUJQ5syzRVZA7flSXq7zYpnhCRbOi5gBmbY#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:> .
@prefix ns1: <http://wordnet-rdf.princeton.edu/lemma/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/triples/select?fl=TRIPLE_UID,%20CORD_UID,%20SUBJECT,%20PREDICATE,%20WORDNET_SEMREL,%20%20OBJECT,%20PRED_POSITION,%20SUBJECT_CUIS,%20OBJECT_CUIS,%20UMLS_SEMREL,%20PRED_POSITION,%20PREDICATE-LEMMA&q=CORD_UID:8snyy5zp&rows=> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  <https://uts.nlm.nih.gov/uts/umls/concept/C0939237> ns1:reduce <https://uts.nlm.nih.gov/uts/umls/concept/C0035647> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-12-16T19:43:07.924640"^^xsd:dateTime;
    prov:wasGeneratedBy "S&T TWOC project version 2" .
  
  sub:version prov:value "2"^^xsd:integer .
  
  rdf:OBJECT rdfs:label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" .
  
  rdf:OBJECT-POSITION rdfs:label "3"^^xsd:integer .
  
  rdf:PREDICATE rdfs:label "reduced" .
  
  rdf:PREDICATE-POSITION rdfs:label "[101]" .
  
  rdf:SUBJECT rdfs:label "remdesivir for both 5 and 10 days , lopinavir / ritonavir , and dexamethasone" .
  
  rdf:SUBJECT-POSITION rdfs:label "35"^^xsd:integer .
  
  rdfs:ABSTRACT-UID ns3:50 "8snyy5zp" .
  
  rdfs:SENTENCE rdfs:label "Compared to standard care, remdesivir for both 5 and 10 days, lopinavir/ritonavir, and dexamethasone reduced the risk of any severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40% (0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively." .
  
  rdfs:TRIPLE-UID ns2:8snyy5zp-TRIPLE-ABSTRACT-1 "8snyy5zp-TRIPLE-ABSTRACT-1" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C0035647> rdfs:label "risk" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C0939237> rdfs:label "lopinavir / ritonavir" .
}

sub:pubInfo {
  sub:assertion prov:wasDerivedFrom <https://www.ncbi.nlm.nih.gov/pubmed/33634043/> .
  
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
    npx:hasSignature "YFt0qxIL7zOz+6ixeNoZiA6ddF2tYpzNplpJZs6K2yt2Veu0gyQ0sa4RENQ5N3k/5cTiolHVYJjQ3MLJY6HJ6wwJVZxcqtPArno9or5bB5e421sCS2MHACWE47KWb2uxzjKztSJD149hqWBdHSUmChIGgeDW040k7vfHWBtVkDA=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-12-16T19:43:07.924640"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}